Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 30, 2026 14:30 ET | Source: Eikon Therapeutics, Inc.

Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology

TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease...
May 30, 2026 14:15 ET | Source: BioNTech SE

Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

BioNTech and BMS' PD-L1xVEGF-A bispecific pumitamig shows encouraging efficacy in patients with non-small cell lung cancer in ROSETTA Lung-02 trial
May 30, 2026 14:15 ET | Source: BioNTech SE

Globale Daten der ROSETTA Lung-02-Studie: Ermutigende Wirksamkeit für BioNTechs und Bristol Myers Squibbs bispezifischen PD-L1xVEGF-A-Immunmodulator-Kandidat Pumitamig bei nicht-kleinzelligem Lungenkrebs

Ermutigende Wirksamkeit für BioNTechs & BMSs bispezifischen PD-L1xVEGF-A-Immunmodulator-Kandidat Pumitamig bei nicht-kleinzelligem Lungenkrebs
May 30, 2026 08:00 ET | Source: Replimune, Inc.

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

WOBURN, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today...
May 30, 2026 08:00 ET | Source: https://immatics.com/

Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting

One-time infusion of IMA203CD8 PRAME cell therapy in the ongoing Phase 1 dose escalation/dose expansion trial achieved anti-tumor activity in platinum-resistant ovarian cancer and in uterine cancer...
May 29, 2026 16:15 ET | Source: Crescent Biopharma, Inc.

Crescent Biopharma Announces Grants of Inducement Awards

WALTHAM, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next...
May 29, 2026 08:00 ET | Source: Replimune, Inc.

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

WOBURN, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today...
May 28, 2026 19:02 ET | Source: TermPlus

TermPlus Fixed-Term Accounts Combine High-Yield Monthly Income With a Three-Layer Protection System and Target Rates from 7.35% Per annum for One-Year and Up To 8.50%* Per Annum for Five-Years

Sydney, Australia, May 29, 2026 (GLOBE NEWSWIRE) -- A growing number of Australians are looking for income-generating options that pair competitive returns with a clear, built-in approach to capital...
May 28, 2026 10:13 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences to Participate in Upcoming Conferences in June

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic...
May 28, 2026 09:10 ET | Source: Medicenna Therapeutics Corp.

Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs

NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO, May 28, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”)...